Santen Pharmaceutical Co (SNPHY) Live Share Price, Invest From India

Santen Pharmaceutical Co Stock Performance

as on August 20, 2026 at 4:44 am IST

$11.93
Day's Price Range
$11.93
$11.93
52 Week's Low
52 Week's High
52-Week Price Range
$11.93
100.00%
Downside
-100.00%
Upside

Santen Pharmaceutical Co share price movements today

Previous Close: $12.06
Open: $11.93
Volume: 2.1K
Market Cap: $3.9B
Dividend Yield: 1.94%
Day's Low - High: $11.93 - $11.93

Santen Pharmaceutical Co Historical Returns

1 Month Return: -7.88 %
3 Month Return: + 2.51 %
1 Year Return: + 13.18 %
3 Year Return: + 29.23 %
5 Year Return: 0 %

Santen Pharmaceutical Co Stock Fundamentals & Key Indicators

Check Santen Pharmaceutical Co market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$3.9B

EPS (TTM)

121.85

Dividend Yield

1.94%

PE Ratio (TTM)

16.41

Industry PE ratio

4.37

PEG Ratio

0.5492015944513537

Return On Equity TTM

13.39%

Santen Pharmaceutical Co Stock Valuation

Track how Santen Pharmaceutical Co P/E has moved over time to understand its valuation trends.

Santen Pharmaceutical Co in the last 5 years

Overview
Trends

Lowest (-29.10x)

March 31, 2024

Industry (4.37x)

March 31, 2026

Today (14.53x)

March 31, 2026

Highest (89.84x)

March 31, 2022

LowHigh

Today’s Price to Earnings Ratio: 14.53x

Santen Pharmaceutical Co vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Santen Pharmaceutical Co with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %	Dividend Yield %
Santen Pharmaceutical Co	NA	$3.9B	NA	16.41	56.10%	1.94%
Eli Lilly & Co	BUY	$1.1T	332.75%	39.68	33.53%	55.300000000000004%
AbbVie	BUY	$440.8B	108.47%	70.68	71.48%	2.7199999999999998%
Johnson & Johnson	BUY	$627.4B	45.07%	30.3	70.45%	2%
Merck & Company	BUY	$335.1B	72.32%	108.67	4.77%	247.88000000000002%

See all

Stock Returns calculator for Santen Pharmaceutical Co Stock including INR - Dollar returns

The Santen Pharmaceutical Co stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

Santen Pharmaceutical Co investment value today

Current value as on today

₹1,23,409

Returns

₹23,409

(+23.41%)

Returns from Santen Pharmaceutical Co Stock

₹12,230 (+12.23%)

Dollar Impact

₹11,179 (+11.18%)

Indian Investors' Interest in Santen Pharmaceutical Co Stock

Search interest for Santen Pharmaceutical Co Stock has increased by 85% in the last 30 days, reflecting an upward trend in search activity.

Time period: July 21, 2026 to August 20, 2026

Change:85% versus previous 30 day period

Santen Pharmaceutical Co Quarterly Profit & Loss

All numbers in Millions USD

	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Total Revenue	79,251	72,389	73,417	77,027	79,132	74,771	70,347	74,199	82,346	69,865
Gross Profit	51,750	42,365	43,986	44,882	45,088	42,766	38,471	39,239	50,584	38,186
Operating Income	7,057	12,750	12,350	11,058	2,383	13,155	10,516	10,460	17,386	8,168
EBITDA	10,688	17,067	16,595	15,744	20,587	17,863	15,557	15,651	22,024	12,948
Interest Expense	790	168	486	703	1,683	407	422	323	521	747
Depreciation	4,104	4,031	4,902	4,685	4,560	4,707	4,773	4,699	4,637	4,780
Income Before Tax	5,794	12,868	11,207	9,484	-3,685	13,450	10,362	10,630	19,721	8,444
Income Tax Expense	4,689	2,456	2,344	2,179	-3,808	2,843	2,231	2,338	3,873	1,149
Net Income	1,116	10,414	8,866	7,332	29	10,633	8,203	8,017	15,830	7,288
Net Profit Margin	65.30%	58.52%	59.91%	58.27%	56.98%	57.20%	54.69%	52.88%	61.43%	54.66%

Santen Pharmaceutical Co Annual Profit & Loss

All numbers in Millions USD

	Mar 2017	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Total Revenue	199,096	224,942	234,026	241,555	249,605	266,257	279,037	301,965	309,211
Gross Profit	124,130	138,564	143,262	146,724	151,384	156,586	166,087	178,709	170,677
Operating Income	32,479	38,691	45,098	33,535	37,798	35,886	-3,090	38,541	47,941
EBITDA	42,786	49,698	56,967	51,057	70,276	52,930	12,949	50,716	67,406
Interest Expense	1,565	434	2,881	2,393	1,488	1,209	1,499	2,664	2,114
Depreciation	9,882	10,896	10,969	16,573	16,768	17,055	17,249	18,178	19,465
Income Before Tax	31,822	39,261	43,117	32,091	12,418	35,616	-5,799	29,874	50,303
Income Tax Expense	8,768	4,000	11,174	10,377	5,773	8,427	9,184	3,171	10,476
Net Income	21,724	35,261	31,954	23,618	6,830	27,218	-14,948	26,642	39,622
Net Profit Margin	62.35%	61.60%	61.22%	60.74%	60.65%	58.81%	59.52%	59.18%	55.20%

Santen Pharmaceutical Co Quarterly Cash Flow

All numbers in Millions USD

	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Net Income	1,105	10,412	8,862	7,306	123	10,633	8,203	8,017	15,830	7,288
Operating Cash Flow	8,667	2,544	25,188	31,708	13,209	12,139	6,018	9,249	21,590	5,327
Investing Cash Flow	-3,177	-2,700	-1,084	-1,945	-416	-1,016	-7,622	-1,991	-1,136	-911
Financing Cash Flow	-9,226	-13,761	-5,902	-11,657	-2,711	-18,936	-21,257	-11,930	-375	-7,990
Change in Cash	-3,317	-12,393	19,218	17,302	12,552	89,744	-23,281	-5,919	18,490	-4,334

Santen Pharmaceutical Co Annual Cash Flow

All numbers in Millions USD

	Mar 2017	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Net Income	23,054	35,261	31,943	21,714	6,645	27,189	-14,983	26,642	39,613
Operating Cash Flow	10,843	42,843	32,894	39,947	38,808	46,043	37,147	72,649	46,123
Investing Cash Flow	-28,201	-8,259	-2,935	-5,175	-53,355	-35,169	-26,777	-6,145	-13,756
Financing Cash Flow	-28,657	-17,631	-28,107	-12,729	-16,685	5,557	-37,220	-34,031	-52,324
Change in Cash	-47,516	17,001	1,513	20,634	-28,542	20,126	-25,111	36,679	-18,139

Mutual Funds that own Santen Pharmaceutical Co Stock

Check out the Mutual Funds with significant holdings in Santen Pharmaceutical Co.

Funds	Holdings	Shares Held
Trust for Professional Managers	0.012482%	40231

Insights on Santen Pharmaceutical Co

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

NO EFFECT
Against Peers
In the last 1 year, Eli Lilly & Co. has given 74.3% return, outperforming this stock by 64.1%
NO EFFECT
Against Peers
In the last 3 years, Eli Lilly & Co. has given 124.3% return, outperforming this stock by 94.7%
NEGATIVE IMPACT
Revenue Fall
Revenue is down for the last 2 quarters, 82.34B → 69.86B (in $), with an average decrease of 15.2% per quarter
NEGATIVE IMPACT
Price Dip
In the last 1 month, SNPHY stock has moved down by -7.6%
NEGATIVE IMPACT
Profit Down
Netprofit is down for the last 2 quarters, 15.83B → 7.28B (in $), with an average decrease of 54.0% per quarter

About Santen Pharmaceutical Co

Santen Pharmaceutical Co., Ltd. engages in the research and development, production, and marketing of pharmaceuticals and medical devices in Japan, China, Asia, Europe, the Middle East, Africa, and internationally. The company operates through Medical drugs, Over-the-counter drugs, Medical equipment, and others segments. It products include Taflupro/Timolol maleate, a combination drug of a prostaglandin Fa derivative and a beta-blocker for the treatment of glaucoma and ocular hypertension area; omidenepagisopropyl, an EP2 receptor agonist that is in phase II clinical trial for the treatment of glaucoma and ocular hypertension area; cepetaprost, an FP/EP3 receptor agonist that is in phase II clinical trial for the treatment of glaucoma and ocular hypertension area; latanoprost, a prostaglandin Fa derivative emulsified eye drops; netalusdil mesylate, a ROCK/NET inhibitor; Netalus, a combination drug of a ROCK inhibitor and a prostaglandin Fa derivative; netalusdyl mesialate/latanoprost, a combination drug of a ROCK inhibitor and a prostaglandin Fa derivative that is in phase I clinical trial for the treatment of glaucoma and ocular hypertension area. The company also provides cyclosporine, which is used for vernal catarrhal infections; olodaterol hydrochloride, used for dry eye that is in late-stage Phase 11 trial for the treatment of Keroconjunctival disease; olodaterol hydrochloride, used for allergic conjunctivitis that is in the Phase I/Early Phase II trial for the treatment of Keroconjunctival disease; epinastine hydrochloride, an eyelid cream formulation for allergic conjunctivitis; epinastine, a high-dose eye drop formulation for allergic conjunctivitis; nintedanib, a drug targeting pterygium that is in late-stage Phase II trial for the treatment of Keroconjunctival disease; and eflimrufuspalfa, which is used for diabetic macular edema. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Kita, Japan.

Organisation	Santen Pharmaceutical Co
Headquarters	Grand Front Osaka Tower A, Kita, Japan, 530-8552
Industry	Drug Manufacturers - General
CEO	Mr. Takeshi Ito
E-voting on shares	Click here to vote

Key Management of Santen Pharmaceutical Co

Name	Title
Mr. Takeshi Ito	President, CEO & Representative Director
Mr. Daisuke Nakata	Chief Digital & Information Officer
Ms. Mika Masunari	Corporate Officer, General Counsel, Chief Risk Officer & Chief Compliance Officer
Mr. Kenji Morishima	Corporate Officer & Head of China Product Development Department
Ms. Rie Nakajima	COO & Director
Mr. Kazuo Koshiji	CFO & Corporate Officer
Ms. Kaori Itagaki	General Manager of Investor Relations Group
Ms. Marianthi Psacha	Corporate Officer, Head of EMEA Business and International Pricing Market Access & Public Affairs
Mr. Shinichi Teramachi	Corp. Officer, Head of Sales and Head of Japan Sales & Marketing
Ms. Yoko Saiki	Corporate Officer & Chief Human Resources Officer

FAQs

What is Santen Pharmaceutical Co share price today?

Santen Pharmaceutical Co share price today is $11.93 as on August 19, 2026 at 11:14 pm IST at the close of the market. Santen Pharmaceutical Co share today touched a day high of $11.93 and a low of $11.93.

What is the 52 week high and 52 week low for Santen Pharmaceutical Co share?

Santen Pharmaceutical Co share touched a 52 week high of $0.00 on January 1, 1970 and a 52 week low of $0.00 on January 1, 1970. Santen Pharmaceutical Co stock price today i.e. August 19, 2026 at 11:14 pm IST is closed at $11.93,which is -Infinity% down from its 52 week high and Infinity% up from its 52 week low.

What is Santen Pharmaceutical Co's market capitalisation today?

Santen Pharmaceutical Co market capitalisation is $0.00T as on August 19, 2026 at 11:14 pm IST.

How to invest in Santen Pharmaceutical Co Stock (SNPHY) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Santen Pharmaceutical Co on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Santen Pharmaceutical Co Shares that will get you 0.1257 shares as per Santen Pharmaceutical Co share price of $11.93 per share as on August 19, 2026 at 11:14 pm IST.

What is the minimum amount required to buy Santen Pharmaceutical Co Stock (SNPHY) from India?

Indian investors can start investing in Santen Pharmaceutical Co (SNPHY) shares with as little as ₹95.743 or $1 (as of August 20, 2026 at 4:38 am IST) using the INDmoney app.
For example: If you want to invest $10 or ₹957.43 in Santen Pharmaceutical Co stock (as per the Rupee-Dollar exchange rate as on August 20, 2026 at 4:38 am IST). Based on Santen Pharmaceutical Co share’s latest price of $11.93 as on August 19, 2026 at 11:14 pm IST, you will get 0.8382 shares of Santen Pharmaceutical Co. Learn more about fractional shares .